Evidence map›Paper›PMID 33047210›Full record

ArticleInternational journal of colorectal disease2021

IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease.

Beatriz Piantoni Gonçalves, Tamires Flauzino, Cláudia Junko Inoue, Jaqueline Costa Castardo de Paula, Talita Cristina Galvão, Camila Cataldi de Alcantara, Paula Kikuchi Miyazaki, Lucilene Rosa, Silva Westmore, Marcell Alysson Batisti Lozovoy and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of colorectal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. The Impact of Genetic Variation on Drug Response in Adult IBD: A Systematic Review.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Beatriz Piantoni GonçalvesLaboratory of Research in Applied Immunology, State University of Londrina, Londrina, PR, Brazil.
Tamires FlauzinoLaboratory of Research in Applied Immunology, State University of Londrina, Londrina, PR, Brazil.
Cláudia Junko InoueLaboratory of Research in Applied Immunology, State University of Londrina, Londrina, PR, Brazil.
Jaqueline Costa Castardo de PaulaLaboratory of Research in Applied Immunology, State University of Londrina, Londrina, PR, Brazil.
Talita Cristina GalvãoLaboratory of Research in Applied Immunology, State University of Londrina, Londrina, PR, Brazil.
Camila Cataldi de AlcantaraLaboratory of Research in Applied Immunology, State University of Londrina, Londrina, PR, Brazil.
Paula Kikuchi MiyazakiLaboratory of Research in Applied Immunology, State University of Londrina, Londrina, PR, Brazil.
Lucilene Rosa
Silva WestmoreOutpatient Clinic of Gastroenterology, University Hospital, State University of Londrina, Londrina, PR, Brazil.
Marcell Alysson Batisti LozovoyDepartment of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University Hospital, State University of Londrina, Av. Robert Koch 60, Londrina, PR, 86038-440, Brazil.
Edna Maria Vissoci ReicheDepartment of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University Hospital, State University of Londrina, Av. Robert Koch 60, Londrina, PR, 86038-440, Brazil.
Andréa Name Colado SimãoDepartment of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University Hospital, State University of Londrina, Av. Robert Koch 60, Londrina, PR, 86038-440, Brazil. deianame@yahoo.com.br.ORCID http://orcid.org/0000-0002-2073-6782
Universidade Estadual de Londrina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of the present study was to evaluate the IL6 -174 G>C (rs1800795) and -572 G>C (rs1800796) genetic variants and their association with inflammatory bowel diseases (IBDs), disease activity, and response to TNF-α inhibitors.

methodsThe study included 178 patients with IBD and 224 healthy controls. Among the IBD patients, 66 of them were in use of TNF-α inhibitors therapy and were followed during 48 weeks and categorized as responders and non-responders.

resultsIn total, 89 (50.0%) had ulcerative colitis (UC) and 89 (50.0%) had Crohn's disease (CD). The IL6 -572 CC genotype presented a protective effect in CD patients in codominant and recessive models, while the IL6 -174 CC genotype was associated with susceptibility to UC and CD. The presence of G/C haplotype in the recessive model (GCGC) was associated with UC. The Crohn's disease endoscopic index of severity was low in those patients carrying the GCGC haplotype. It was observed that there was no association between the IL6 genetic variants and TNF-α inhibitor therapy response.

conclusionThe G/C haplotype (recessive model) was associated with susceptibility to UC but not to CD. However, the G/C haplotype (dominant model) was associated with the endoscopic activity of CD. Moreover, these IL6 variants did not predict the TNF-α inhibitor therapy response.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesGenetic Predisposition to DiseaseHaplotypesHumansInterleukin-6Polymorphism, Single NucleotideIL6 protein, humanInterleukin-6Inflammatory bowel diseases, Ulcerative colitis, Crohn’s disease, interleukin 6 genetic variant, rs1800796, rs1800795

Identifiers

PMID33047210
OpenAlexW3092432292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.